Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $16.15 and last traded at $16.05, with a volume of 503141 shares changing hands. The stock had previously closed at $14.71.
A number of equities analysts have commented on ARQT shares. Needham & Company LLC reaffirmed a "buy" rating and set a $18.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday, November 7th. HC Wainwright assumed coverage on shares of Arcutis Biotherapeutics in a research report on Monday, December 30th. They set a "buy" rating and a $19.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $16.20.
Check Out Our Latest Stock Report on Arcutis Biotherapeutics
The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -8.61 and a beta of 1.30. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46. The firm has a 50-day simple moving average of $11.98 and a two-hundred day simple moving average of $10.51.
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.33) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.09. The firm had revenue of $44.76 million during the quarter, compared to analysts' expectations of $38.05 million. Arcutis Biotherapeutics had a negative net margin of 140.97% and a negative return on equity of 119.11%. On average, sell-side analysts anticipate that Arcutis Biotherapeutics, Inc. will post -1.34 EPS for the current fiscal year.
In related news, insider Masaru Matsuda sold 5,015 shares of the firm's stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $8.68, for a total value of $43,530.20. Following the sale, the insider now owns 178,273 shares of the company's stock, valued at $1,547,409.64. This trade represents a 2.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Howard G. Welgus sold 10,000 shares of the business's stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $8.65, for a total transaction of $86,500.00. Following the transaction, the director now owns 171,944 shares of the company's stock, valued at $1,487,315.60. This trade represents a 5.50 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,291 shares of company stock worth $927,966. Corporate insiders own 9.50% of the company's stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ARQT. Suvretta Capital Management LLC increased its holdings in shares of Arcutis Biotherapeutics by 7.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 10,721,511 shares of the company's stock valued at $99,710,000 after acquiring an additional 717,019 shares during the last quarter. GSA Capital Partners LLP increased its stake in Arcutis Biotherapeutics by 730.0% in the third quarter. GSA Capital Partners LLP now owns 237,174 shares of the company's stock valued at $2,206,000 after purchasing an additional 208,599 shares during the last quarter. Rubric Capital Management LP increased its stake in Arcutis Biotherapeutics by 11.7% in the third quarter. Rubric Capital Management LP now owns 10,966,672 shares of the company's stock valued at $101,990,000 after purchasing an additional 1,150,000 shares during the last quarter. Wesbanco Bank Inc. acquired a new stake in Arcutis Biotherapeutics during the third quarter worth approximately $955,000. Finally, Algert Global LLC lifted its position in shares of Arcutis Biotherapeutics by 595.9% during the 3rd quarter. Algert Global LLC now owns 72,480 shares of the company's stock worth $674,000 after buying an additional 62,065 shares during the last quarter.
Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arcutis Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcutis Biotherapeutics wasn't on the list.
While Arcutis Biotherapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.